No Data
No Data
Express News | A-share dividends, cash dividends and bonus shares: 3 stocks have equity registration today.
Tibet Rhodiola Pharmaceutical Holding Semi-annual Report for 2023
Summary of Tibet Rhodiola Pharmaceutical Holding's H1 2024 report.
Tibet Pharmaceutical (600211): Sales of neovactin are growing rapidly
Incident: The company released its 2023 annual report, achieving annual revenue of 3.13 billion yuan, +22.7% year-on-year, and realized net profit of 800 million yuan, +116.6% year-on-year, net profit of 780 million yuan after deducting non-return to mother net profit of 780 million yuan, year-on-year.
Tibet Pharmaceutical (600211): New actin production capacity is about to be released, negative effects will be released, and a light package will be launched
Performance: In 2023, we achieved revenue of 3.13 billion yuan (+22.9%), net profit of 80 million yuan (+116.6%) to mother, and net profit of 780 million yuan (+112.5%) after deducting non-net profit. Selling expenses 17.57
Tibet Pharmaceutical (600211.SH): Received 86.2 million yuan in industrial support funds
Gelonghui, March 29丨Tibet Pharmaceutical (600211.SH) announced that the company and its subsidiary, Tibet Nordicom Pharmaceutical Co., Ltd. received 86,202,742 yuan in industrial development support funds from the Shannan Happy Home Construction Administration on March 29, 2024, accounting for 10.76% of the company's most recent (2023) audited net profit attributable to shareholders of listed companies.
No Data